Compare Adaptive Biotechnologies Corp (ADPT) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Chipotle Mexican Grill, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Chipotle Mexican Grill, Inc. trades at $33.36 (market cap $44.06B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 13.2× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Chipotle Mexican Grill, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | CMG | |
|---|---|---|
Market Cap | $3.33B | $44.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $56.41 |
52-Week Low | $10.24 | $28.17 |
Enterprise Value | $3.19B | $48.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Chipotle Mexican Grill (CMG) trades at $34.35, down 2.91% over 24 hours, with a bullish technical signal from moving averages and strong fundamentals including a 49.23% ROE and consistent earnings beats. Revenue grew to $11.93B in 2025, though net cash flow turned negative due to aggressive financing activities. Recent news highlights operational excellence and menu innovation as growth drivers amid competitive pressures.
Outlook remains positive with a $40.46 analyst consensus price target (70% buy ratings), but risks include cost inflation and softer comps. The stock offers upside from execution of expansion plans, yet investors face headwinds from consumer sentiment and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
